Sanofi (France)
NEWS
Dengvaxia is approved for dengue disease caused by serotypes 1-4 in people 9 through 16 years of age who are living in areas of the U.S. who have had a laboratory-documented previous infection.
Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.
This week has a number of approvals expected by the U.S. Food and Drug Administration. Let’s take a look.
The French drugmaker expanded its one-year-old Valyou Savings Program to lower the cost of up to 10 boxes of pens and 10 boxes of vials to $99 per month.
Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
The French company has an age limit for its top official and the company is working on a succession plan in anticipation of that change.
It’s a busy week for the U.S. Food and Drug Administration (FDA) with quite a number of pending drug approvals, several of which were delayed for a variety of reasons. Here’s a look.
The U.S. Food and Drug Administration has been busy approving new treatments for various diseases. Two days into the new week and the regulatory agency has green lit two therapeutics, while other companies are planning to file for potential approval.
The next couple of weeks look to be busy for the FDA, with a string of target action dates scheduled. This week marks three scheduled approvals, two for extra indications for already-approved biologics, and the third for a combination treatment for glaucoma. Here’s a look.
JOBS
IN THE PRESS